Promino Announces Closing of Private Placement
Burlington, Ontario--(Newsfile Corp. - January 30, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FSE: 93X) ("Promino" or the "Company") is pleased to announce that, further to its press releases dated December 18, 2025 and January 19, 2026, the Company has closed its private placement, issuing a total of 37,380,433 units ("Units") at a price of $0.03 per Unit for gross proceeds of $1,121,413 (the "Private Placement"). Each Unit consist
Food / Beverages, Sports, Health
2026-01-30 7:42 PM EST | Promino Nutritional Sciences, Inc.
NuGen Medical Devices Inc. Announces CFO Transition
Toronto, Ontario--(Newsfile Corp. - January 30, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, announces that Veronique Laberge has resigned from her position as Chief Financial Officer and Corporate Secretary. Her resignation is effective January 31, 2026. The Company has appointed Mr. Ajay Mishra as Chief Financial Officer and Corporate Secretary, effective January 31, 2026. Mr. M
Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-30 5:15 PM EST | NuGen Medical Devices Inc.
Edison Issues Report on Picton Property Income (PCTN)
London, United Kingdom--(Newsfile Corp. - January 30, 2026) - Edison issues report on Picton Property Income (LSE: PCTN) Picton Property Income (PCTN) has published its Q326 trading update. NAV per share increased by 0.9% to 102.4p, the sixth successive quarterly increase, driven by like-for-like property valuation gains and retained earnings. Including DPS paid, the NAV total return was 1.8%, building on the 3.4% return in H126. Q1 DPS was 1.12x covered. Operationally, PCTN is focused
Banking / Financial Services, Computer Hardware, Computer Software, Health
2026-01-30 10:17 AM EST | Edison Group
Delivra Health Brands Announces Appointment of New Director
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2026) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health", "Delivra" or the "Company"), a consumer packaged goods company uniquely positioned in the health and wellness sector, is pleased to announce the appointment today of John Barrett as a director of the board of directors of the Company (the "Board"). Mr. Barrett was previously a senior executive with Frito Lay an
Cannabis, Health, Cannabis Extractor, Cannabis Manufacturer
2026-01-30 7:25 AM EST | Delivra Health Brands Inc.
HPN Holdings, Inc. Announces Closing of the Acquisition of Orange Auto Insurance
Chicago, Illinois--(Newsfile Corp. - January 29, 2026) - HPN Holdings, Inc. (OTCID: KICK) ("HPN" or the "Company") today announced the successful closing of its acquisition of Orange Auto Insurance ("Orange"), a technology-driven nonstandard automobile insurance holding company and its managing general agency (Orange Underwriters, LLC). Orange will operate as a wholly owned subsidiary of HPN. The combined operating companies will continue to trade on the OTCIQ Market under the ticker symbol
2026-01-29 8:15 AM EST | HPN Holdings, Inc.
Adia Nutrition Announces Documentary Featuring WWE/TNA Superstar Elias/Elijah Jeff Sciullo's Recovery with Adia Med's AdiaVita Stem Cell Treatment
Winter Park, Florida--(Newsfile Corp. - January 28, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its medical division Adia Med specializing in regenerative therapies, is proud to announce an upcoming documentary chronicling the recovery of professional wrestler Jeff Sciullo—known to fans as Elias in WWE and Elijah in TNA—from a tricep injury sustained in June 2025. The film will focus on his treatment with Adia Med's AdiaVita, a high-potency stem cell product delivering over
Healthcare and Hospitals, Health
2026-01-28 10:00 AM EST | Adia Nutrition Inc.
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
Montreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing collaboration with Canadian Nuclear Laboratories ("CNL") as part of its strategic effort to accelerate and expand its proprietary radiopharmaceutical program. Defence has been collaborating with CNL on th
Biotechnology, Pharmaceuticals, Health
2026-01-28 8:40 AM EST | Defence Therapeutics Inc.
Hear At Last Holdings Inc (HRAL) and GG&C Collaborate to Present New Housing Model to Jamaican Government
Miami, Florida--(Newsfile Corp. - January 28, 2026) - Hear At Last (OTCID: HRAL) on January 27/26 in collaboration with GG&C, is proud to announce the successful delivery of a comprehensive housing model for presentation to the Jamaican Government. This innovative model is designed to provide a framework for addressing the nation's housing needs and will enable key decision-makers to determine the best path forward for future housing development initiatives. The housing model presen
Household / Consumer / Cosmetics, Health
2026-01-28 8:00 AM EST | Hear AtLast Holdings, Inc
Izotropic Provides Corporate Update & Announces Non-Brokered Private Placement
British Columbia and Sacramento, California--(Newsfile Corp. - January 28, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, provides a corporate update and announces the intention to complete a small non-brokered private placement fina
2026-01-28 8:00 AM EST | Izotropic Corporation
Scryb Reports Fiscal 2025 Results; Strengthened Balance Sheet and Significant Cybeats Exposure
Toronto, Ontario--(Newsfile Corp. - January 28, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company") announces that it has filed its audited consolidated financial statements and Management's Discussion and Analysis for the fiscal year ended September 30, 2025 ("FY2025"). The filings are available on SEDAR+. Fiscal 2025 marked a transformative year for Scryb, highlighted by a materially strengthened balance sheet, significantly reduced operating costs, and a
Biotechnology, Healthcare and Hospitals, Health
2026-01-28 7:03 AM EST | Scryb Inc.
Invitation to Cosmo's Full Year 2025 Financial Results Webcast on 9 March 2026
Dublin, Ireland--(Newsfile Corp. - January 28, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Full-Year 2025 results on Monday, 9 March 2026 at 7:00 am CET. Live conference call and audio webcast presentation: Cosmo invites investors, financial analysts and business/life sciences journalists to a live webcast presentation which will follow on the same da
Healthcare and Hospitals, Health
2026-01-28 1:24 AM EST | Cosmo Pharmaceuticals N.V.
Neural's Portfolio Company Hanf.com Announces Sales Start of Ritual Herbs Nicotine and Tobacco Free Products
Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CB
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-27 10:00 AM EST | Neural Therapeutics Inc.
Beckett's CEO Issues Shareholder Letter and The Company Announces Board Change
Ontario and Los Angeles, California--(Newsfile Corp. - January 27, 2026) - Beckett's Inc. (CSE: BKTS), a fast-growing non-alcoholic beverage brand shaking up the NA category, announces that Beckett's Chief Executive Officer, Larry Weintraub has issued a shareholder letter providing a recap on 2025 and an outlook for 2026. The Company also announces a change to its Board. Shareholder Letter from Larry Weintraub: Beckett's 2025 Recap and 2026 Outlook Dear Shar
Food / Beverages, Cannabis, Health
2026-01-27 7:30 AM EST | Becketts Inc.
Predictmedix AI Rebrands as QScreen AI Inc., (QAI) Harnessing Quantum-AI Synergy for Health Screening
Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP0) (formerly Predictmedix AI Inc.), a pioneering leader in artificial intelligence enabled health and safety technology, is pleased to announce that, further to its news releases of January 12, 2026, the Company has completed its name change to QScreen AI Inc. (the "Name Change"). As a result of the Name Change the Company's common shares (the "Common Shares") are expe
2026-01-27 7:01 AM EST | QScreen AI Inc.
Adia Nutrition Announces Every Child in Autism Stem Cell Study Receives Umbilical Cord Blood-Derived Stem Cell Treatments Three Times - Open Nationwide and Worldwide with Participation Cost
Winter Park, Florida--(Newsfile Corp. - January 26, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its subsidiary Adia Med of Winter Park, LLC, today highlighted key details of its ongoing IRB-approved clinical study for children with Autism Spectrum Disorder (ASD), listed on ClinicalTrials.gov (NCT07304440). The trial ensures every participating child in Phase One or Phase Two receives umbilical cord blood-derived stem cell and exosome treatments (AdiaVita) three times, administered mont
Healthcare and Hospitals, Health
2026-01-26 10:00 AM EST | Adia Nutrition Inc.
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ. Robert Bitterman, CEO and Chairman of th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-26 8:15 AM EST | Phio Pharmaceuticals Corp.
Aleen Inc. Personal Account: Streamlined Navigation for Wellness Information
Toronto, Ontario--(Newsfile Corp. - January 26, 2026) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, announces the rollout of enhanced navigation features within the Personal Account, its user-facing service for managing wellness information. The improvements focus on simplifying how users browse, locate, and interact with their wellness documents. By offering more intuitive menus, faster access paths, and clearer categorization, the updates aim to make personal w
2026-01-26 8:00 AM EST | Aleen Inc.
Cheelcare Announces Medicare and Medicaid Services Reimbursement Approval for Companion Power Assist Device, Expanding U.S. Market Access
Investment Highlights: U.S. Medicare and Medicaid reimbursement eligibility achieved: The Company has received Pricing, Data Analysis, and Coding ("PDAC") verification, enabling U.S. Medicare and Medicaid reimbursement for its Companion power assist device. Companion is a best-in-class, front-mounted add-on for manual wheelchairs that provides motorized assistance, helping users enable a higher quality of life.
2026-01-26 7:30 AM EST | Cheelcare Inc.
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme. The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 n
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-26 7:00 AM EST | Optimi Health Corp.
TempraMed Launches New Product "VIVI Med(TM)," Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications
Highlights Uses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature medications at optimal temperature Designed for medications beyond standard insulin pens, including vials, biologics, GLP-1 therapies, alternative epinephrine auto-injectors, and temperature- and light-sensitive glucose test strips Expanded portfolio to pursue larger
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-23 4:05 PM EST | TempraMed Technologies Ltd